Press Releases from MOLOGEN (1 total)
Active principle for cancer medication MGN1703 proven
MOLOGEN AG has taken a significant step forward in the development of its cancer medication. A further evaluation sequence of data from the company’s clinical study shows by means of biomarkers the potential of the active ingredient in the therapy of cancer.
MOLOGEN AG has evaluated a further sequence of clinical data from the completed phase Ib trial with the cancer medication MGN1703. The analysis of biomarkers of the patients’…
Go To Page: 1
